We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Cerus Corporation (CERS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6950 |
| Open | 1.7400 |
| Bid | 1.7400 x 600 |
| Ask | 1.8100 x 600 |
| Day's Range | 1.7300 - 1.9600 |
| 52 Week Range | 1.2100 - 3.0800 |
| Volume | |
| Avg. Volume | 1,654,706 |
| Market Cap | 317.245M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.13 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CERS
Related Research
- Cerus CorporationCYTK: Raising target price to $79.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.RatingFair ValueEconomic Moat4 days agoArgus Research
Business WireCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif., March 26, 2024--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories
Business WireCerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CONCORD, Calif., March 19, 2024--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive
GuruFocus.comInsider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
On March 14, 2024, William Greenman, President and Chief Executive Officer of Cerus Corp (NASDAQ:CERS), sold 125,926 shares of the company, according to a recent SEC Filing.
GuruFocus.comInsider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
Cerus Corp (NASDAQ:CERS), a company specializing in the field of blood transfusion safety with its innovative INTERCEPT Blood System, has reported an insider transaction involving its Chief Operating Officer, Vivek Jayaraman.
Simply Wall St.Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
It's been a good week for Cerus Corporation ( NASDAQ:CERS ) shareholders, because the company has just released its...
GuruFocus.comCerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
Full-Year 2024 Revenue Guidance Reiterated Amidst Sequential Revenue Growth
Insider MonkeyCerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript March 5, 2024 Cerus Corporation reports earnings inline with expectations. Reported EPS is $-0.01 EPS, expectations were $-0.01. Cerus Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and […]
Simply Wall St.Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Cerus ( NASDAQ:CERS ) Full Year 2023 Results Key Financial Results Revenue: US$156.4m (down 3.5% from FY 2022). Net...
Business WireCerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
CONCORD, Calif., March 05, 2024--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| CGEN Compugen Ltd. | |||
| VCYT Veracyte, Inc. | |||
| MCRB Seres Therapeutics, Inc. | |||
| BCRX BioCryst Pharmaceuticals, Inc. | |||
| CRIS Curis, Inc. |
Similar to CERS
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| MASS 908 Devices Inc. | |||
| PACB Pacific Biosciences of California, Inc. | |||
| DCTH Delcath Systems, Inc. | |||
| RCEL AVITA Medical, Inc. | |||
| ALUR Allurion Technologies Inc. |
Analyst Price Targets (4)
Upgrades & Downgrades
| Initiated | Craig-Hallum: to Buy | 4/12/2024 | |
| Reiterates | Stephens & Co.: Equal-Weight to Equal-Weight | 3/7/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/6/2024 | |
| Downgrade | BTIG: Buy to Neutral | 1/20/2023 | |
| Maintains | Stifel: to Buy | 5/27/2020 | |
| Maintains | Stephens & Co.: to Overweight | 4/16/2020 |
Company Profile
1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com
Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 625
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
